Clinical Trial Update: Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) [Phase 1]

View source ↗

Summary

A Phase 1 safety study of ridaforolimus (AP23573) in patients with progressive or recurrent glioma has completed, including glioblastoma and gliosarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma
• Malignant Glioma

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Glioma, Glioblastoma | Phase 1 | Status: COMPLETED